Navigation Links
Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
Date:9/19/2012

SAN DIEGO, Sept. 19, 2012 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that FierceBiotech named Celladon as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's tenth annual Fierce 15 selection.

"You don't often find three Big Pharmas clustered together in a single venture round earmarked for a mid-stage heart-failure drug. But there they were – Pfizer, Novartis and Johnson & Johnson – all backing Celladon's big $53 million round earlier this year," says FierceBiotech Editor John Carroll. "And once you check out the positive mid-stage efficacy data for Celladon's innovative new gene therapy MYDICAR – now being tested in an expanded Phase IIb confirmatory study – you can see for yourself why they'd want a front-row seat. We'll be watching as well."

"We are proud to join this prestigious group of innovative companies and for our team's recognition as a Fierce 15 Company. There is a tremendous need for novel treatment options for patients with advanced heart failure. The Celladon team is working passionately to provide patients with this debilitating condition with a new therapeutic alternative," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corporation. "Together with our investors, we are also grateful to the clinical investigators and patients who participate in novel trials and thereby make advances in medicine possible."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition.

An internationally recognized daily newsletter reaching more than 100,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
2. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Neogen Corporation Announces 2nd Quarter Results Conference Call
5. Luminex Corporation to Present at JP Morgan Healthcare Conference
6. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
7. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
8. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
9. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
10. Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results
11. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... 31, 2014 The Global and ... and in-depth study on the current state of ... China. , The report provides a basic overview ... chain structure. Global market analysis and Chinese domestic ... history, developments, trends and competitive landscape of the ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... A major challenge before new biotechnology ... realm of Boston-Cambridge, is gaining visibility that can lead ... the Director of Boston’s Adult Stem Cell Technology Center, ... visibility of his company an important priority since he ... to a social media marketing campaign launched ...
(Date:8/28/2014)... 28, 2014 “This kit has an improved ... from 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin ... benefit to plant owners and USDA-GIPSA inspection agencies that have ... Testing can take place in a matter of minutes with ... plant test the feed and grain before accepting it, but ...
Breaking Biology Technology:Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 2Electrical Insulating Varnish Market World, China Regional Analysis & 2020 Forecasts Available at DeepResearchReports.com 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4
... 11 AtriCure, Inc.,(Nasdaq: ATRC ), a ... surgical,ablation products, today announced that the first patient ... Richard Kaplon, a,well-known cardiac surgeon, performed the procedure ... purpose of the ABLATE clinical trial is to ...
... 11, Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA ... ), announced today that,they have entered into a ... Possis Medical in a cash tender offer for ... of approximately US-Dollar 361,million. The offer price represents ...
... Ltd. announced that the,quantitative analysis of Replikin Count(TM) ... H5N1 cycle is over. Sporadic outbreaks may,continue, but ... expected to subside - until the next rapid ... begins., 140,000 virus protein sequences were analyzed ...
Cached Biology Technology:AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 2Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 3Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 4Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 5Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement 6FluForecast(R) Replikin Count(TM) Predicts That the H5N1 Cycle Which Began in 1996 Is Now Over 2
(Date:9/1/2014)... The week-long discussions and decisions of the Nomenclature Section ... Melbourne, Australia in July 2011. This meeting is held ... premier experts on the rules for naming algae, fungi ... rule book for naming the organisms they study. This ... Code of Nomenclature for algae, fungi, and plants, which ...
(Date:8/31/2014)... bacteria C. diff , that causes diarrhoea, temperature ... at the University of Leicester. , Using a mass ... possible to identify the unique ,smell, of C. ... the condition., What is more, the Leicester team say ... the disease simply from their smell a chemical ...
(Date:8/31/2014)... the last 19 years reveals that fresh water from melting ... to rise by 2cm more than the global average of ... rapid rise in sea-level by studying satellite scans of a ... , The melting of the Antarctic ice sheet and ... of around 350 gigatonnes of freshwater to the surrounding ocean. ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2
... been inspiring debate across the scientific community since the ... wider discussion about open access publishing has advanced to ... its first few articles (please see http://f1000research.com/articles ). ... further articles will be published on the current consultation ...
... have long known that the body rids itself of excess ... liver and excreting them through the liver,s bile. However, a ... 22 in PLoS ONE suggests that when this ... A molecule sequesters only that mineral and routes it from ...
... new genetic mutation that causes familial amyotrophic lateral sclerosis ... Gehrig,s Disease, has been identified by a team of ... Medical School (UMMS). Mutations to the profilin (PFN1) gene, ... nerve cell axons, is estimated to account for one ...
Cached Biology News:First articles now live on F1000 Research 2First articles now live on F1000 Research 3Copper's previously unknown exit strategy 2Copper's previously unknown exit strategy 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3